Literature DB >> 20691464

Change in International Prostate Symptom storage subscore after long-term medical therapy in BPH patients: finasteride and alpha-blocker combination therapy in men with moderate-to-severe LUTS/BPH in Korea.

Ji Youl Lee1, Seung Hwan Lee, Su Jin Kim, Choung-Soo Kim, Hyun Moo Lee, Cheon Il Kim, Byung Ha Chung.   

Abstract

OBJECTIVE: To evaluate the efficacy and the change of International Prostate Symptom Score (IPSS) storage subscore after combination therapy (α-blocker and finasteride) in patients with lower urinary tract symptoms (LUTS) consistent with moderate-to-severe benign prostatic hyperplasia (BPH) and compared with α-blocker-only treatment.
METHODS: A total of 1315 patients seen in 5 urology centers in Korea from January 2001 to August 2007, with LUTS secondary to BPH were enrolled. Patients were divided into 4 groups according to treatment pattern (α-blocker monotherapy vs combination therapy) and IPSS storage subscores (≥6 vs <6). The changes from baseline in prostate volume, prostate-specific antigen concentration, IPSS, and Q(max.) were analyzed. We also determined the statistical differences among 4 groups in the IPSS, Q(max.), quality of life score (QoL), and prostate volume.
RESULTS: Of the 1315 men, 217 (16.5%) completed the month 48 visit. All groups showed significant improvements in the IPSS total score, IPSS voiding subscores, and QoL at 1 year. However, the high storage subscore group at baseline showed a significantly higher improvement in IPSS total scores and IPSS voiding subscores compared with the low storage subscore group at year 4. IPSS storage subscores were improved only in patients with high storage subscores at baseline, especially in combination treatment group. The mean change in QoL score from baseline to year 4 was significantly improved in high storage subscore groups.
CONCLUSIONS: Data from this retrospective analysis suggest that long-term combination treatment would be beneficial, especially to patients with severe storage symptoms at baseline. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20691464     DOI: 10.1016/j.urology.2010.05.033

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

Review 1.  [Combined treatment of BPS with tamsulosin and finasteride : Literature review and prescription data].

Authors:  K Höfner; S Ulrich; R Berges
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

2.  α-blocker monotherapy and α-blocker plus 5-alpha-reductase inhibitor combination treatment in benign prostatic hyperplasia; 10 years' long-term results.

Authors:  Teak Jun Shin; Chun Il Kim; Choal Hee Park; Byung Hoon Kim; Young Kee Kwon
Journal:  Korean J Urol       Date:  2012-04-18

3.  Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia.

Authors:  Kang Jun Cho; Se Hee Kang; Hyo Sin Kim; Jun Sung Koh; Joon Chul Kim
Journal:  Int Neurourol J       Date:  2011-09-30       Impact factor: 2.835

4.  Diagnostic Tool for Assessing Overactive Bladder Symptoms: Could the International Prostate Symptom Storage Subscore Replace the Overactive Bladder Symptom Score?

Authors:  Ji Sung Shim; Jae Heon Kim; Hoon Choi; Jae Young Park; Jae Hyun Bae
Journal:  Int Neurourol J       Date:  2016-09-23       Impact factor: 2.835

5.  Efficacy and tolerability of Roystonea regia lipid extract (D-004) and terazosin in men with symptomatic benign prostatic hyperplasia: a 6-month study.

Authors:  Raúl Guzmán; Julio C Fernández; Manuel Pedroso; Lilia Fernández; José Illnait; Sarahí Mendoza; Ana T Quiala; Zunilda Rodríguez; Jilma Mena; Aylim Rodíguez; Marbelis Campos; Carlos Sánchez; Yanet Alvarez; Gladys Jiménez
Journal:  Ther Adv Urol       Date:  2019-06-11

6.  Chinese urologists' views of practice patterns in the diagnosis and treatment of benign prostatic hyperplasia: a nationwide survey.

Authors:  Nan Wu; Jian Sun; Pulin Yu; Zhenqiu Sun
Journal:  Int Neurourol J       Date:  2012-12-31       Impact factor: 2.835

7.  Current status of 5α-reductase inhibitors in prostate disease management.

Authors:  Dong Il Kang; Jae Il Chung
Journal:  Korean J Urol       Date:  2013-04-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.